drugset / Trial / NCT00997750
Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome
Phase 4
Completed
85 enrolled
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine whether nonsteroidal antiinflammatory drug lornoxicam in combination with low dose aspirin (100mg/day) is effective and safe in patients with Acute Coronary Syndrome without persistent ST-segment elevation.
Timeline
- Start
- 2007-03
- Primary completion
- 2008-12
- Completion
- 2009-06
Publications
- Background Lomakin N.V., Gruzdev A.K. Cardiovascular risks of cyclooxygenase inhibitors (data review). Kardiol serdecno-sosud hir #1:28-36, 2009 (http://www.mediasphera.ru/journals/cardsurg/530/eng/8095/)
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lornoxicam | Small molecule | 8 mg | — |
| Subject | Lornoxicam | Small molecule | 12 mg | — |